

Randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) versus standard practice chemotherapy in patients with limited small cell lung cancer (SCLC) and good performance status

Submission date 06/04/2000	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 06/04/2000	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 02/09/2022	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/lu21-chemotherapy-for-small-cell-lung-cancer>

Contact information

Type(s)

Scientific

Contact name

Dr Danielle Andrews

Contact details

MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00002822

Protocol serial number

LU21

Study information

Scientific Title

Randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) versus standard practice chemotherapy in patients with limited small cell lung cancer (SCLC) and good performance status

Study objectives

To compare an intensive regimen of VICE without dose reduction but with dose delay permitted versus standard practice chemotherapy in patients with limited stage SCLC and good performance status

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cancer

Interventions

1. One group receives intensive regimen of VICE without dose reduction but with dose delay permitted
2. The other group receives standard practice chemotherapy

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE)

Primary outcome(s)

Survival time, quality of life

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/12/2001

Eligibility

Key inclusion criteria

1. Previously untreated SCLC
2. Limited disease
3. WHO 0-2
4. Normal blood count
5. Glomerular Filtration Rate (GFR) greater than 65 ml/min

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Total final enrolment

402

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/12/1995

Date of final enrolment

01/12/2001

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/11/2005		Yes	No
Plain English results			02/09/2022	No	Yes